Relevant bibliographies by topics / Sodium-glucose cotransporter type 2 inhibitor

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Sodium-glucose cotransporter type 2 inhibitor'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sodium-glucose cotransporter type 2 inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sodium-glucose cotransporter type 2 inhibitor"

1

Petunina, N. A., E. V. Goncharova, M. Е. Теlnova, I. A. Kuzina, N. S. Martirosyan, and A. Yu Sochneva. "Modern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozin." Meditsinskiy sovet = Medical Council, no. 6 (May 12, 2023): 234–40. http://dx.doi.org/10.21518/ms2022-032.

Full text
Abstract:
Diabetes mellitus, a well-known risk of cardiovascular disease (CVD), in patients with type 2 diabetes mellitus (DM2) Hyperglycemia has been found to be an increased risk of coronary heart disease and mortality. In real clinical practice, physicians are faced with the problem of choice when prescribing new hypoglycemic drugs in patients with type 2 diabetes and high cardiovascular risk. Modern possibilities and approaches to the treatment of DM2 have contributed to the creation of a promising class of hypoglycemic drugs that block renal glucose reabsorption - inhibitors of the sodium-glucose c
APA, Harvard, Vancouver, ISO, and other styles
2

Klinkner, Gwen, and Maggie Steingraber-Pharr. "Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report." AACN Advanced Critical Care 34, no. 1 (2023): 27–32. http://dx.doi.org/10.4037/aacnacc2023830.

Full text
Abstract:
Sodium-glucose cotransporter-2 inhibitors are now considered second-line treatment agents for type 2 diabetes and offer a unique treatment approach with added cardiorenal benefits. Drugs in this class increase the risk of euglycemic diabetic ketoacidosis, which may be difficult to diagnose if clinicians are not aware of the risk factors and subtle symptoms. This article describes a case of euglycemic diabetic ketoacidosis in a patient with coronary artery disease who was taking a sodium-glucose cotransporter-2 inhibitor and experienced acute mental status changes immediately after heart cathet
APA, Harvard, Vancouver, ISO, and other styles
3

Hendryx, Michael, Yi Dong, Jonas M. Ndeke, and Juhua Luo. "Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis." PLOS ONE 17, no. 9 (2022): e0274519. http://dx.doi.org/10.1371/journal.pone.0274519.

Full text
Abstract:
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs. Emerging findings from laboratory studies indicate that SGLT2 inhibitors can improve liver function and suppress the proliferation of hepatocellular carcinoma (HCC) cells. The aim of this study was to test the hypothesis that initiation of SGLT2 inhibitors improves HCC prognosis in a human population. Methods We used National Surveillance, Epidemiology and End Results (SEER)—Medicare linked data in the United States to evaluate the role of SGLT2 inhibitor initiation on the survival
APA, Harvard, Vancouver, ISO, and other styles
4

Martha Lilac Ketisha Antoine, Malyn, and Yancheng Xu. "Sodium-glucose cotransporter-2 inhibitors: current knowledge on the use of canagliflozin, dapagliflozin and empagliflozin in the treatment of type 2 diabetes mellitus." International Journal of Medicine 8, no. 1 (2020): 8. http://dx.doi.org/10.14419/ijm.v8i1.30308.

Full text
Abstract:
Sodium-glucose cotransporter-2 inhibitors are considered the newest class of medication developed for the treatment of type 2 diabetes mellitus. This class of drug reduces blood glucose levels by decreasing glucose absorption at the level of the kidneys. Through their mechanism of action, drugs within this class exhibit the ability to reduce blood pressure, fasting blood glucose and body weight. The common side effects observed with the use of sodium-glucose cotransporter-2 inhibitors include: genital mycotic infections, intravascular volume depletion and dehydration. To date, much is already
APA, Harvard, Vancouver, ISO, and other styles
5

Kelemen, Hajnal, Petra-Edina Mărcuțiu, and Adrienn Rausz. "New oral antidiabetics – pharmaceutical chemical characterization of sodium-glucose cotransporter-2 inhibitors." Bulletin of Medical Sciences 96, no. 1 (2023): 107–23. https://doi.org/10.2478/orvtudert-2023-0009.

Full text
Abstract:
Abstract Selective sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent a novel, innovative class of oral antidiabetic agents for the treatment of type 2 diabetes. The first sodium-glucose transporter (SGLT) inhibitor to be discovered was a naturally occurring O-glycoside, phlorizin, which is found in a number of plants, including the bark of the apple tree root. Although it can lower blood glucose levels, it is not used for this purpose because it is not a selective inhibitor. The structure of the lead molecule, phlorizin, has been further developed into the SGLT-2 inhibitors that are
APA, Harvard, Vancouver, ISO, and other styles
6

Mishra, Rahul, Ghada Elshimy, Lakshmi Kannan, and Rishi Raj. "Sodium–glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis." BMJ Case Reports 15, no. 7 (2022): e250942. http://dx.doi.org/10.1136/bcr-2022-250942.

Full text
Abstract:
A man in his late 50s, with uncontrolled type 2 diabetes mellitus (T2DM) and morbid obesity, presented to the hospital with complicated epididymo-orchitis. The onset of symptoms (scrotal pain, erythema and swelling) occurred after the use of empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, for 2 months. His baseline antidiabetic medications were insulin, glipizide and metformin. Initially, he had failed treatment of epididymo-orchitis with oral levofloxacin for 3 weeks, followed by 2 weeks of doxycycline therapy. At the presentation to the hospital, an ultrasound of the scrot
APA, Harvard, Vancouver, ISO, and other styles
7

Alipour, Meysam, Jalal Rezaei, Venus Shahabi Rabori, et al. "Limb amputation following sodium-glucose cotransporter type 2 inhibitor therapy." Journal of Preventive Epidemiology 10, no. 1 (2024): e38251. https://doi.org/10.34172/jpe.2025.38251.

Full text
Abstract:
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i
APA, Harvard, Vancouver, ISO, and other styles
8

Hamza Shabbir, Muhammad Rasikh, Khalid Bashir, et al. "Impact of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Events in Type 2 Diabetes." Indus Journal of Bioscience Research 3, no. 1 (2025): 320–24. https://doi.org/10.70749/ijbr.v3i1.496.

Full text
Abstract:
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder marked by persistent hyperglycemia and insulin resistance. Objective: The main objective of the study is to find the impact of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors on cardiovascular events in Type 2 diabetes. Methodology: This randomized control trial was conducted at Shalamar Hospital, Lahore, from 1st March to 31st August 2024. Data were collected from 195 patients. Data were collected at baseline and subsequent follow-up visits through standardized protocols. Results: Data were collected from 195 pati
APA, Harvard, Vancouver, ISO, and other styles
9

Faizan, Khorajiya* Dr. Khushbu Patel Khushbu Patel Dr. C. N. Patel. "Review Of the Combination Dosage Form of Sitagliptin Phosphate Monohydrate and Dapagliflozin Propanediol Monohydrate as an Anti-Diabetic Agent." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 2020–27. https://doi.org/10.5281/zenodo.15391282.

Full text
Abstract:
Sitagliptin acting as Anti-Diabetic agent (Dipeptidyl peptidase-4 inhibitor) which boosts post prandial insulin release decreases Glucagon secretion and lower mean time as well as fasting blood glucose in type 2 diabetes mellitus. There is a strong rationale for combining a DPP-4i and a SGLT2i in patients with T2D because the two drugs exert different and complementary glucose-lowering effects. Dual therapy (initial combination or stepwise approach) is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin. This agent is used in combina
APA, Harvard, Vancouver, ISO, and other styles
10

Umapathysivam, Mahesh M., Bethany Morgan, Joshua M. Inglis, et al. "SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis." JAMA Network Open 7, no. 3 (2024): e242744. http://dx.doi.org/10.1001/jamanetworkopen.2024.2744.

Full text
Abstract:
This cohort study examines the natural history and response to treatment of sodium glucose cotransporter 2 (SGLT2) inhibitor–associated ketoacidosis compared with that of type 1 diabetes–associated ketoacidosis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Sodium-glucose cotransporter type 2 inhibitor"

1

Park, Sin-Hee. "Evaluation du rôle des co-transporteurs sodium-glucose SGLT1 et 2 dans l'induction de la sénescence et de la dysfonction des cellules endothéliales à l'aide d'une approche in vitro et in vivo." Thesis, Strasbourg, 2019. http://www.theses.fr/2019STRAJ041.

Full text
Abstract:
Les inhibiteurs du cotransporteur sodium-glucose SGLT2 ont montré des effets protecteurs cardiovasculaires remarquables avec une réduction du risque de mortalité cardiovasculaire et d’hospitalisation pour insuffisance cardiaque chez des patients atteints de DT2 avec un risque cardiovasculaire élevé, un effet indépendant du contrôle de la glycémie. La possibilité que les inhibiteurs de SGLT1 et 2 protègent le système cardiovasculaire en ciblant la fonction endothéliale protectrice reste incertaine. La première étude in vitro indique que l'angiotensine II et les microparticules circulantes prove
APA, Harvard, Vancouver, ISO, and other styles
2

Ferreira, Diogo Jorge Rosa. "Sodium-glucose cotransporter-2 inhibitors in heart failure : mechanisms and effects in patients with and without type 2 diabetes mellitus." Master's thesis, 2020. http://hdl.handle.net/10451/47730.

Full text
Abstract:
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2020<br>Apesar dos avanços notáveis no tratamento da insuficiência cardíaca (IC), esta continua a ser uma das principais causas de mortalidade e de morbilidade nas sociedades ocidentais. Os inibidores do co-transportador de sódio e glucose 2 (iSGLT2), uma nova classe terapêutica projetada inicialmente para reduzir a glicémia em doentes com diabetes mellitus do tipo 2 (DM2), emergiram como uma abordagem terapêutica promissora na IC. Os ensaios clínicos de segurança cardiovascular (ECSC) mos
APA, Harvard, Vancouver, ISO, and other styles
3

Liw, Ya-Wen, and 劉雅雯. "Synthesis of C-aryl D-glucofuranosides as Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Treatment." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/47149817847460875232.

Full text
Abstract:
碩士<br>國立臺灣大學<br>藥學研究所<br>99<br>A wide range of medications available for type 2 diabetes (T2DM) are inadequate to maintain the glycemic control at HbA1c &amp;lt;7%, hence development of novel drug with different mechanism of action is desirable. Type 2 sodium-dependent glucose co-transporter (SGLT2) is a 672-amino acid, high capacity, low affinity transporter express nearly exclusively in the S1 segment of the renal proximal tubule. Since SGLT2 mediates the majority of renal glucose reabsorption from the glomerular filtrate, inhibiting SGLT2 is believed to be able to decrease the glucose leve
APA, Harvard, Vancouver, ISO, and other styles
4

"Investigation on the anti-diabetic effects of selected natural products/Chinese herbs by inhibiting the activity of sodium-glucose cotransporter 2 (SGLT2)." 2012. http://library.cuhk.edu.hk/record=b5549132.

Full text
Abstract:
糖尿病是一種以不正常的高血糖為主要特徵的長期性的糖代謝紊亂疾病。二型糖尿病是常見的糖尿病類型，多於九成的糖尿病病人患有此種類型。各種引起糖尿病的病因最終都會導致血糖過高，並且最終會引起有關眼睛，腎臟，神經和血管系統的併發癥。迄今，糖尿病正影響著大約世界6%的人口，而現在患病率依然在逐年增加。在香港，由於高能量的食和缺乏運動，越來越多的老年人和青年人正在遭受著糖尿病的困擾。糖尿病不是一種致命性的疾病，但是如果沒有採取好的治療控制措施，糖尿病最終會引起一些併發癥，這些併發癥最終會使糖尿病患者走向死亡。高血糖癥不僅是糖尿病的主要特徵，而且也是引起各種糖尿病併發癥的重要因素，在二型糖尿病的治療當中，根據各種病理因素，市場上已經研製出了很多西藥來治療糖尿病。然而，它們都有一些副作用的限制。因此，我們需要通過綜合治療和通過新的途徑研製新的製劑來控制血糖水平，保護病人遠離長期併發癥的困擾。如今，腎臟在血糖平衡中的重要角色已經被很好的認知。 在過去的二十年裡， 通過減少血糖在腎臟的重吸收來增加尿液中血糖的排出，從而達到降低體內血糖水平的方法已經被提出并認為是治療糖尿病的一直新的途徑。 在腎臟中，鈉葡萄糖共轉運體2（SGLT 2）主要負責葡萄糖的重吸收，因此，鈉葡萄糖共轉運體2（SGLT 2）抑製劑被認為是一種有潛質的新型的治療糖尿病的製劑。然而，市場上至今沒有成功研製這種製劑。达格列嗪（dapag
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Sodium-glucose cotransporter type 2 inhibitor"

1

Nandave, Mukesh. "Cardiovascular and Renal Diseases in Type 2 Diabetes." In Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7568-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nandave, Mukesh. "SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes." In Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7568-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Braem, Alan, Prashant P. Deshpande, Bruce A. Ellsworth, and William N. Washburn. "Discovery and Development of Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Dapagliflozin for the Treatment of Type 2 Diabetes." In Topics in Medicinal Chemistry. Springer International Publishing, 2014. http://dx.doi.org/10.1007/7355_2014_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Seferović, Petar M., Francesco Cosentino, Giuseppe Rosano, and James Januzzi. "Sodium–glucose cotransporter 2 inhibitors." In The ESC Textbook of Heart Failure, edited by Petar M. Seferović, Andrew J. S. Coats, Gerasimos Filippatos, Stefan D. Anker, Johann Bauersachs, and Giuseppe Rosano. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780198891628.003.0050.

Full text
Abstract:
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed as a novel therapy for type 2 diabetes mellitus (T2DM). However, several SGLT2 inhibitors demonstrated favourable effects on cardiovascular and kidney events, as well as attenuation in hospitalization for heart failure (HF), in patients with T2DM, including those with chronic kidney disease (CKD). In patients with HF with reduced ejection fraction, dapagliflozin and empagliflozin proved effective in reducing the risk of cardiovascular mortality and HF hospitalization, regardless of T2DM status or background the
APA, Harvard, Vancouver, ISO, and other styles
5

Gilbert, Matthew, and Amy Shah. "Case 16: A Case of Euglycemic Diabetic Ketoacidosis After Initiation of Ketogenic Diet in a Patient With Type 2 Diabetes on a Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor." In Diabetes In Practice: Case Studies with Commentary. American Diabetes Association, 2021. http://dx.doi.org/10.2337/9781580407663.16.

Full text
Abstract:
A 52-year-old Caucasian female with a past medical history of well-controlled type 2 diabetes, hypertension, and dyslipidemia presented to the emergency department with a 3-day history of severe headache associated with nausea, neck pain, and photophobia. Her outpatient diabetes regimen consisted of metformin 1,000 mg twice a day, linagliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) 5 mg daily, and empagliflozin (a sodium–glucose cotransporter 2 [SGLT2] inhibitor) 25 mg daily. She reported starting a ketogenic diet 4 months before admission with an objective 17-lb weight loss after she had
APA, Harvard, Vancouver, ISO, and other styles
6

Duchon, Olga, and Celeste Thomas. "Case 14: Euglycemic Ketoacidosis in the Setting of COVID-19 Infection and Sodium–Glucose Cotransporter 2 Inhibitor Use." In Diabetes In Practice: Case Studies with Commentary. American Diabetes Association, 2021. http://dx.doi.org/10.2337/9781580407663.14.

Full text
Abstract:
A 26-year-old man with a 3-year history of type 2 diabetes was admitted to the hospital with respiratory illness and abdominal symptoms attributed to coronavirus disease 2019 (COVID-19) infection. He had a history of intermittent insulin use and three or four hospital admissions for diabetic ketoacidosis (DKA) within the first 2 years of diagnosis. In the 3 months before this admission, he again discontinued insulin therapy but continued the sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin and glipizide that was prescribed by his primary care provider.
APA, Harvard, Vancouver, ISO, and other styles
7

Mudaliar, Sunder. "Sodium-glucose Cotransporter Type-2 Inhibitors in the Treatment of Type 2 Diabetes." In Diabetology: Type 2 Diabetes Mellitus. Jaypee Brothers Medical Publishers (P) Ltd., 2014. http://dx.doi.org/10.5005/jp/books/12165_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Soliman, Diana, and Nicole Jelesoff. "Case 15: Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use." In Diabetes In Practice: Case Studies with Commentary. American Diabetes Association, 2021. http://dx.doi.org/10.2337/9781580407663.15.

Full text
Abstract:
A 79-year-old male with type 2 diabetes diagnosed at age 49 years presented with worsening generalized weakness, subacute functional decline, nausea, vomiting, diarrhea, and decreased oral intake. He had a history of regionally advanced melanoma and hypophysitis with development of secondary adrenal insufficiency and hypothyroidism related to treatment with ipilimumab and nivolumab.
APA, Harvard, Vancouver, ISO, and other styles
9

"Diabetes and lipid metabolism." In Best of Five MCQs for the Endocrinology and Diabetes SCE, edited by Atul Kalhan. Oxford University Press, 2022. http://dx.doi.org/10.1093/oso/9780198864615.003.0006.

Full text
Abstract:
This chapter covers core curriculum topics related to diabetes and lipid metabolism. The diagnosis, investigation, classification, and pathophysiology of Type 1 and Type 2 diabetes mellitus is discussed in detail. A table has been used to sum up the clinical characteristics of monogenic diabetes subtypes in a concise though comprehensive manner. The MCQs have been updated to reflect current clinical practice guidelines of the National Institute for Health and Care Excellence and Joint British Diabetes Societies. MCQs have been added which evaluate a trainee’s knowledge on the management of dia
APA, Harvard, Vancouver, ISO, and other styles
10

Bailey, Clifford J., and Melanie J. Davies. "Non-Insulin Glucose-Lowering Agents." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0253.

Full text
Abstract:
A selection of differently acting blood glucose-lowering agents can be used in the management of type 2 diabetes to address different aspects of disease pathogenesis and comorbidities. Key factors influencing choice of medication include extent and duration of hyperglycaemia, obesity, insulin resistance, and impairment of beta-cell function, risk of hypoglycaemia, and risk or presence of cardiovascular, renal, and other complications. Diet, other lifestyle measures, patient education, and empowerment are fundamental throughout. Metformin is still widely used as initial orally administered bloo
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Sodium-glucose cotransporter type 2 inhibitor"

1

Al-Shamasi, Al-Anood, Meram Elsayed, Nabeel Abdulrahman, Jensa Joseph, and Fatima Mraiche. "The Cardiovascular benefits of Empagliflozin, a Sodium Glucose Cotransporter Inhibitor: Is NHE1 a viable target?" In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0228.

Full text
Abstract:
Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attention due to a recent clinical trial, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). In this trial, treatment with EMPA over 2.6 years decreased cardiovascular vascular events (14% reduction). Whether EMPA induces cardioprotection, independent of diabetes remains unclear. A previous report has demonstrated that EMPA inhibited NHE1 activity, which led to a reduction in intracellular sodium and calcium. In our study, we examine the cellular interplay b
APA, Harvard, Vancouver, ISO, and other styles
2

Ishiwata, S., T. Kasai, A. Sato, et al. "Effect of Sodium Glucose Cotransporter 2 Inhibitor on Sleep Apnea in Chronic Heart Failure Patients with Type 2 Diabetes Mellitus." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4684.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

LV, WEN-TAO, QIU-MEI ZHANG, and XIANG-WEN MENG. "EFFECT OF SGLT-2 INHIBITOR ON BONE TURNOVER IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES." In 2021 International Conference on Education, Humanity and Language, Art. Destech Publications, Inc., 2021. http://dx.doi.org/10.12783/dtssehs/ehla2021/35720.

Full text
Abstract:
To investigate the effect of sodium glucose cotransporter 2 inhibitor (SGLT-2I) on bone turnover markers in overweight and obese patients with type 2 diabetes mellitus. Methods: according to the criteria of selection and exclusion, 42 patients with overweight and obese type 2 diabetes (BMI≥25kg/m2) were selected from October 2019 to May 2020. The patients were randomly divided into experimental group and control group, there were 18 cases in the experimental group and 24 cases in the control group. The experimental group was treated with SGLT-2I, and other oral hypoglycemic agents (or insulin)
APA, Harvard, Vancouver, ISO, and other styles
4

Martinez, D. Blanquez, M. Hayon Ponce, A. Caballero Romero, et al. "CP-009 Risk assessment of diabetes ketoacidosis in type 2 diabetes mellitus patients treated with sodium–glucose cotransporter type 2 inhibitors." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shanmugavel Geetha, H., M. V. Gogtay, N. R. Perkit, et al. "Association of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor Use and Chronic Obstructive Pulmonary Disease (COPD) Outcomes Amongst Patients With Type 2 Diabetes Mellitus." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5955.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Essa, Asma, Noura Aldous, Fatiha Benslimane, and Huseyin Yalcin. "In Vivo Investigation of Cardiac benefits of Sodium Glucose Cotransporter Inhibition using the Zebrafish Model." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0199.

Full text
Abstract:
Type 2 diabetes mellitus (T2DM) affects &gt;16% of adults in Qatar. Newly emerging class of antidiabetic drugs, focused on SGLT inhibition were observed to reduce CVDs risks in diabetic patients. Up to date, the mechanism contributing to the CV benefits remains unrevealed. Zebrafish embryos were injected with different morpholinos to knockdown SGLT genes and study their effects on cardiac parameters. SGLT1 inhibition caused the most severe effects on zebrafish embryos with survival rate ~10 %. It also caused tube-like structured heats with edema, affecting significantly the cardiac output and
APA, Harvard, Vancouver, ISO, and other styles
7

Shanmugavel Geetha, H., M. V. Gogtay, N. R. Perkit, S. Ravichandran, A. Sekar, and G. M. Abraham. "Implications of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor Use in the Incidence of Asthma and Chronic Obstructive Pulmonary Disease (COPD) Amongst Patients With Type 2 Diabetes Mellitus." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5956.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yokose, C., G. Challener, B. Jiang, et al. "POS0939 SERUM URATE CHANGE AMONG GOUT PATIENTS TREATED WITH SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS VS. SULFONYLUREA: A COMPARATIVE EFFECTIVENESS ANALYSIS." In EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria. BMJ Publishing Group Ltd and European League Against Rheumatism, 2024. http://dx.doi.org/10.1136/annrheumdis-2024-eular.5810.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hazwani, I., RMR Raja Abdul Wafy, and AM Abdul Muizz. "APCU 29 Exploring the effects of sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) in elderly patients with heart failure with reduced ejection fraction (HFrEF), with and without type 2 diabetes mellitus (T2DM)." In APCU@USM 2024 abstracts. British Cardiovascular Society, 2025. https://doi.org/10.1136/openhrt-2024-apcu.29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kou, CH, SC Shao, LT Kuo, and ECC Lai. "5PSQ-199 Use of sodium glucose cotransporter 2 inhibitors and risk of fracture in type 2 diabetes patients: a multi-institutional cohort study in Taiwan." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.318.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Sodium-glucose cotransporter type 2 inhibitor"

1

Yeh, Jia-Ai, Yu-Chang Liu, and Huei-Kai Huang. Relative Risk of Nephrolithiasis in Type 2 Diabetes Patients Using Sodium-Glucose Cotransporter 2 Inhibitors Compared to Those Using DPP-4 Inhibitors or GLP-1 Receptor Agonists: A Protocol of Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.10.0087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shi, Xiaojing, Hongmei Gao, Ruirui Song, Fang liu, Jun chen, and Jian Huang. Effect of sodium-glucose cotransporter 2 inhibitor on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.3.0008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

GHOSAL, SAMIT, A. K. Singh, and A. K. Das. Triple Drug Fixed Dose Combination Of Sodium-Glucose Co-transporter 2 Inhibitor, Dipeptidyl Peptidase-4 Inhibitor And Metformin In Type 2 Diabetes In India: A Systematic Review With Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.3.0022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Sodium-glucose cotransporter type 2 inhibitor' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography